Analysis of the key differences between erlotinib and gefitinib

Erlotinib and gefitinib, two targeted therapeutic drugs for non-small cell lung cancer (NSCLC), have shown efficacy in patients with EGFR gene-sensitive mutations.

Erlotinib is the world's first small molecule inhibitor of EGFR tyrosine kinase, especially suitable for EGFR Metastatic NSCLC patients with exon 19 deletion or exon 21 (L858R) mutation. Gefitinib is another oral EGFR-TK inhibitor, suitable for the treatment of locally advanced or metastatic NSCLC with EGFR gene-sensitizing mutations.

A study including1122 patients showed that erlotinib was superior to gefitinib in terms of survival benefit, specifically in terms of disease control rate and median overall survival (OS), respectively65.8% versus 58.9%, and 10.7 months versus 9.6 months.

However, the side effects of erlotinib are more obvious than those of gefitinib, especially gastrointestinal reactions (such as diarrhea), skin reactions (such as rash), and liver function abnormalities.

For patients with NSCLC who develop brain metastases, erlotinib shows higher blood-brain barrier penetration rate and cerebrospinal fluid drug concentration, and therefore performs better in controlling brain metastases.

Gefitinib is generally recommended to be taken once daily, while erlotinib may require dose adjustments in some cases based on patient response, especially when used concurrently with other medications that may interact.

BecauseEGFR mutation status is critical to drug response, patients should undergo genetic testing before treatment with either drug. At the same time, side effects should be closely monitored during treatment and corresponding treatment adjustments should be made as needed.